# BOL-DP-o-05 as an Add-On Treatment of Subjects With Newly Diagnosed Type 1 Diabetes Mellitus

> **NCT04102202** · PHASE1,PHASE2 · WITHDRAWN · sponsor: **Breath of Life International Pharma Ltd**

## Conditions studied

- Type1 Diabetes Mellitus

## Interventions

- **DRUG:** BOL-DP-o-05
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04102202
- **Lead sponsor:** Breath of Life International Pharma Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2020-11-15
- **Primary completion:** 2021-03-22
- **Final completion:** 2021-03-22
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Due to company strategic decision
- **Last updated:** 2021-03-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04102202

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04102202, "BOL-DP-o-05 as an Add-On Treatment of Subjects With Newly Diagnosed Type 1 Diabetes Mellitus". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04102202. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*